Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825404 | Clinical Therapeutics | 2013 | 13 Pages |
Abstract
These results indicate that ticagrelor can weakly activate the metabolism of midazolam to its major 1â²-hydroxy metabolite, and at the same time, seems to weakly inhibit midazolam 4â²-hydroxylation. Furthermore, ticagrelor affects both hepatic and intestinal CYP3A activity.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Renli PhD, Kathleen MD,